The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Abstract This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A "Guidance" document is different from a "Guideline." Guidelines are developed by a multidisciplinary panel of experts and rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations, Assessment Development, and Evaluation (GRADE) system. A guidance document is developed by a panel of experts in the topic, and guidance statements, not recommendations, are put forward to help clinicians understand and implement the most recent evidence. This article is protected by copyright. All rights reserved.

[1]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[2]  Jiayi Hou,et al.  In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[4]  A. Sanyal,et al.  Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis , 2017, Transplantation.

[5]  J. Bosch,et al.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.

[6]  L. Henry,et al.  Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis , 2016, Journal of clinical gastroenterology.

[7]  S. Harrison,et al.  Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2016, Hepatology.

[8]  B. Neuschwander‐Tetri,et al.  In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. , 2016, Gastroenterology.

[9]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[10]  R. Gish,et al.  Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  S. Wild,et al.  Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. , 2016, Journal of hepatology.

[12]  D. Kleiner,et al.  Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. , 2016, Metabolism: clinical and experimental.

[13]  S. Francque,et al.  Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. , 2016, Journal of hepatology.

[14]  P. Newsome,et al.  Non-alcoholic fatty liver disease and liver transplantation. , 2016, Metabolism: clinical and experimental.

[15]  E. Guallar,et al.  Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease , 2016, The American Journal of Gastroenterology.

[16]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[17]  P. Giral,et al.  Fatty liver is an independent predictor of early carotid atherosclerosis. , 2016, Journal of hepatology.

[18]  Yongde Peng,et al.  Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients , 2016, Journal of diabetes research.

[19]  L. Henry,et al.  Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. , 2016, Gastroenterology.

[20]  S. Sookoian,et al.  How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? , 2016, Gastroenterology.

[21]  V. Wong,et al.  Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. , 2016, Journal of hepatology.

[22]  P. Bedossa,et al.  Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[23]  G. Marchesini,et al.  Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? , 2016, Diabetes & metabolism.

[24]  P. Kantoff,et al.  Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[25]  L. Henry,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. , 2016, Clinics in liver disease.

[26]  Dermot F. Reilly,et al.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.

[27]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[28]  V. Wong,et al.  Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease , 2016, Journal of gastroenterology and hepatology.

[29]  A. Schoepfer,et al.  Therapy: Positioning of dilation in eosinophilic oesophagitis , 2016, Nature Reviews Gastroenterology &Hepatology.

[30]  Robert W Platt,et al.  Pioglitazone use and risk of bladder cancer: population based cohort study , 2016, British Medical Journal.

[31]  L. VanWagner,et al.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease , 2016, Current Hepatology Reports.

[32]  N. Afdhal,et al.  Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016 , 2016, Digestive Diseases and Sciences.

[33]  E. Tapper,et al.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease , 2016, The American Journal of Gastroenterology.

[34]  R. Niknam,et al.  The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study , 2016, Middle East journal of digestive diseases.

[35]  B. Motta,et al.  The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage , 2016, Hepatology.

[36]  P. Kuo,et al.  Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. , 2016, Journal of clinical lipidology.

[37]  R. Idilman,et al.  A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease , 2016, Acta radiologica.

[38]  T. Yamanaka,et al.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.

[39]  R. Wiesner,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States , 2016, Transplantation.

[40]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[41]  K. Cusi,et al.  Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. , 2016, The Journal of clinical endocrinology and metabolism.

[42]  Alexandra N. Schlein,et al.  Accuracy and the effect of possible subject‐based confounders of magnitude‐based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference , 2016, Journal of magnetic resonance imaging : JMRI.

[43]  R. Chung,et al.  Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis , 2016, Digestive Diseases and Sciences.

[44]  L. Henry,et al.  Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis , 2016, Expert review of gastroenterology & hepatology.

[45]  A. Hofman,et al.  Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study , 2016, Hepatology.

[46]  H. El‐Serag,et al.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  J. Stoker,et al.  Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment , 2016, International Journal of Obesity.

[48]  F. Aucejo,et al.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis , 2016, Hepatology International.

[49]  Y. Terauchi,et al.  Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution , 2015, BMC Gastroenterology.

[50]  O. Yokosuka,et al.  Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. , 2015, World journal of gastroenterology.

[51]  L. Henry,et al.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.

[52]  N. Schork,et al.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.

[53]  Aijaz Ahmed,et al.  Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  D. Lawlor,et al.  The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis , 2015, PloS one.

[55]  M. Budoff,et al.  Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. , 2015, Atherosclerosis.

[56]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[57]  L. Pacifico,et al.  A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[58]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[59]  N. Chalasani,et al.  Pharmacotherapy for Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[60]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[61]  Ronac Mamtani,et al.  Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. , 2015, JAMA.

[62]  K. Fujioka.  Current and emerging medications for overweight or obesity in people with comorbidities , 2015, Diabetes, obesity & metabolism.

[63]  M. Gosho,et al.  Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. , 2015, Nutrition.

[64]  N. Alkhouri,et al.  A Comprehensive Review of Noninvasive Liver Fibrosis Tests in Pediatric Nonalcoholic Fatty Liver Disease , 2015, Current Gastroenterology Reports.

[65]  A. Mazur,et al.  Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. , 2015, The Journal of pediatrics.

[66]  K. Mahawar,et al.  A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis , 2015, Obesity Surgery.

[67]  Puneet Puri,et al.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[68]  A. Darzi,et al.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology , 2015, Obesity Surgery.

[69]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[70]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[71]  Shasha Zhang,et al.  Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[72]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[73]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[74]  Hirokazu Takahashi,et al.  Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[75]  J. Borén,et al.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.

[76]  J. Zografakis,et al.  Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. , 2015, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[77]  Norbert Gutknecht,et al.  Intrapulpal temperature changes during root surface irradiation with dual-wavelength laser (2780 and 940 nm): in vitro study , 2015, Journal of biomedical optics.

[78]  V. Wong,et al.  Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. , 2015, Journal of hepatology.

[79]  A. Hofman,et al.  Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis , 2015, Diabetologia.

[80]  Amit P. Desai,et al.  Gaps in Recognition and Evaluation of Incidentally Identified Hepatic Steatosis , 2015, Digestive Diseases and Sciences.

[81]  B. Neuschwander‐Tetri,et al.  Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  E. Renner,et al.  Liver transplantation and non-alcoholic fatty liver disease. , 2014, World journal of gastroenterology.

[83]  Anthony Gamst,et al.  Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study , 2014, Hepatology.

[84]  G. Wakabayashi,et al.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments , 2014, Front. Endocrinol..

[85]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[86]  P. Calder,et al.  Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study , 2014, Hepatology.

[87]  M. Yeh,et al.  Pathological features of fatty liver disease. , 2014, Gastroenterology.

[88]  O. Cummings,et al.  No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. , 2014, Gastroenterology.

[89]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[90]  J. Chen,et al.  Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[91]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[92]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[93]  R. Krauss,et al.  Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile , 2014, Lipids in Health and Disease.

[94]  V. Vilgrain,et al.  Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. , 2014, Journal of hepatology.

[95]  M. Sawyer,et al.  Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  R. Bataller,et al.  A histologic scoring system for prognosis of patients with alcoholic hepatitis. , 2014, Gastroenterology.

[97]  S. Wild,et al.  Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.

[98]  H. J. Yoo,et al.  Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study , 2014, Hepatology.

[99]  A. Halbower,et al.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. , 2014, The Journal of pediatrics.

[100]  O. Cummings,et al.  Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. , 2014, The Journal of pediatrics.

[101]  Ian M Thompson,et al.  Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. , 2014, Journal of the National Cancer Institute.

[102]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[103]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[104]  K. Cusi,et al.  Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. , 2014, Journal of hepatology.

[105]  Rohit Loomba,et al.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.

[106]  B. Neuschwander‐Tetri,et al.  Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients , 2013, Hepatology.

[107]  A. Belfiore,et al.  Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment , 2013, International journal of molecular sciences.

[108]  O. Faergeman,et al.  Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. , 2013, International journal of cardiology.

[109]  S. Kaul,et al.  The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. , 2013, The New England journal of medicine.

[110]  M. Al-mallah,et al.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.

[111]  J. Schwimmer,et al.  Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease , 2013, Alimentary pharmacology & therapeutics.

[112]  Luca Valenti,et al.  Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment , 2013, Current pharmaceutical design.

[113]  Richard L Ehman,et al.  Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. , 2013, Radiology.

[114]  Xin Gao,et al.  Liver Fat Content, Evaluated through Semi-Quantitative Ultrasound Measurement, Is Associated with Impaired Glucose Profiles: A Community-Based Study in Chinese , 2013, PloS one.

[115]  S. Pollard,et al.  Increased morbidity in overweight and obese liver transplant recipients: A single‐center experience of 1325 patients from the United Kingdom , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[116]  K. Cusi,et al.  The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus , 2013, Current Diabetes Reports.

[117]  H. J. Yoo,et al.  Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study , 2013, Clinical endocrinology.

[118]  Z. Younossi,et al.  In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. , 2013, Metabolism: clinical and experimental.

[119]  R. Wiesner,et al.  Combined Liver Transplantation and Gastric Sleeve Resection for Patients With Medically Complicated Obesity and End‐Stage Liver Disease , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[120]  N. Chalasani,et al.  Annals of the New York Academy of Sciences Nonalcoholic Fatty Liver Disease: an Emerging Threat to Obese and Diabetic Individuals , 2022 .

[121]  S. Gough,et al.  Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program , 2013, Alimentary pharmacology & therapeutics.

[122]  Bin Wang,et al.  Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2013, Biomedical reports.

[123]  A. Hofman,et al.  Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. , 2012, Journal of hepatology.

[124]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[125]  V. Baracos,et al.  Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[126]  I. Préda,et al.  Heritability of non‐alcoholic fatty liver disease and association with abnormal vascular parameters: A twin study , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[127]  G. Abellán van Kan,et al.  Identifying sarcopenia , 2012, Current opinion in clinical nutrition and metabolic care.

[128]  A. Sanyal,et al.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.

[129]  B. Kasiske,et al.  Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation , 2012, Journal of the American College of Cardiology.

[130]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[131]  A. Suzuki,et al.  Association between puberty and features of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[132]  N. Chalasani,et al.  What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use? , 2012, The American Journal of Gastroenterology.

[133]  T. Saibara,et al.  Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese , 2012, PloS one.

[134]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[135]  Z. Halpern,et al.  Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.

[136]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[137]  D. Kleiner,et al.  Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research , 2012, Seminars in Liver Disease.

[138]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[139]  James E. Nelson,et al.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[140]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[141]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[142]  J. Lavine,et al.  Advances in pediatric nonalcoholic fatty liver disease. , 2011, Pediatric clinics of North America.

[143]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[144]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[145]  G. Nguyen,et al.  Increased perioperative mortality following bariatric surgery among patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[146]  S. Reeder,et al.  Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy , 2011, Journal of magnetic resonance imaging : JMRI.

[147]  A. Kurklinsky,et al.  Bilateral traumatic chylothorax treated by thoracic duct embolization: A rare treatment for an uncommon problem , 2011, Vascular medicine.

[148]  G. Davis,et al.  Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[149]  R. Groszmann,et al.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.

[150]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[151]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[152]  F. Schmitt,et al.  Vitamin E and all-cause mortality: a meta-analysis. , 2011, Current aging science.

[153]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[154]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[155]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[156]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[157]  J. Schulz-Menger,et al.  Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects , 2011, Hepatology.

[158]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[159]  Z. Goodman,et al.  Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS) , 2011, Scandinavian journal of gastroenterology.

[160]  A. Morabito,et al.  Long-term Prevention of Mortality in Morbid Obesity Through Bariatric Surgery. A Systematic Review and Meta-analysis of Trials Performed With Gastric Banding and Gastric Bypass , 2011, Annals of surgery.

[161]  J. Sallis,et al.  Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease , 2011, The American Journal of Gastroenterology.

[162]  F. Ikeda,et al.  Alcohol consumption appears to protect against non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[163]  G. Bedogni,et al.  A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[164]  K. Smidt,et al.  Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS‐1E beta‐cells , 2011, British journal of pharmacology.

[165]  M. Budoff,et al.  Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial , 2011, The American Journal of Gastroenterology.

[166]  J. Sulkes,et al.  Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[167]  O. Cummings,et al.  Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.

[168]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[169]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[170]  N. Chalasani,et al.  Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series , 2010, The American Journal of Gastroenterology.

[171]  E. Bonora,et al.  Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. , 2010, Journal of hepatology.

[172]  T. Liang,et al.  The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease , 2010, Hepatology.

[173]  Cameron D. Palmer,et al.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease , 2010, Hepatology.

[174]  T. Berg,et al.  High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[175]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[176]  A. Hida,et al.  Fatty liver incidence and predictive variables , 2010, Hypertension Research.

[177]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[178]  S. Caldwell,et al.  The Natural History of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[179]  P. Hayes,et al.  Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. , 2010, Alimentary pharmacology & therapeutics.

[180]  L. Rubbia‐Brandt,et al.  Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil” , 2010, American Journal of Gastroenterology.

[181]  G. Marchesini,et al.  HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[182]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[183]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[184]  K. Chayama,et al.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH , 2010, Journal of Gastroenterology.

[185]  U. Akarca,et al.  Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease , 2010, European journal of gastroenterology & hepatology.

[186]  P. Hayes,et al.  Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease , 2009, Alimentary pharmacology & therapeutics.

[187]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[188]  D. Torres,et al.  A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial , 2009, Journal of clinical gastroenterology.

[189]  D. Kleiner,et al.  NASH and cryptogenic cirrhosis: a histological analysis. , 2009, Annals of hepatology.

[190]  A. Feldstein,et al.  Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study , 2009, Hepatology.

[191]  Hajime Sato,et al.  Light and Moderate Alcohol Consumption Significantly Reduces the Prevalence of Fatty Liver in the Japanese Male Population , 2009, The American Journal of Gastroenterology.

[192]  D. May,et al.  Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients , 2009, European journal of gastroenterology & hepatology.

[193]  J. Newton,et al.  Non-Alcoholic Fatty Liver Disease in Older People , 2009, Gerontology.

[194]  F. Pattou,et al.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.

[195]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[196]  A. Bauman,et al.  Independent effects of physical activity in patients with nonalcoholic fatty liver disease , 2009, Hepatology.

[197]  J. Rotter,et al.  Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort , 2009, Obesity.

[198]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[199]  N. Schork,et al.  Heritability of nonalcoholic fatty liver disease. , 2009, Gastroenterology.

[200]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[201]  A. Rissanen,et al.  Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. , 2009, Journal of hepatology.

[202]  R. V. van Dam,et al.  Long‐term effectiveness of diet‐plus‐exercise interventions vs. diet‐only interventions for weight loss: a meta‐analysis , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[203]  Tariq Hameed,et al.  Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[204]  Joshi,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. , 2009, The Journal of the Association of Physicians of India.

[205]  J. Gerss,et al.  The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. , 2009, Cellular and molecular biology.

[206]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[207]  B. McMahon,et al.  Chronic Liver Disease among Alaska-Native People, 2003–2004 , 2009, The American Journal of Gastroenterology.

[208]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[209]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[210]  Raj Vuppalanchi,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.

[211]  G. Salles,et al.  Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[212]  W. Rosenberg,et al.  Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. , 2009, Gastroenterology.

[213]  O. Gedik,et al.  The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease , 2009, Acta Diabetologica.

[214]  M. V. Van Natta,et al.  Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[215]  K. Chayama,et al.  Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. , 2008, Metabolism: clinical and experimental.

[216]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[217]  B. Bell,et al.  Chronic Liver Disease Among Two American Indian Patient Populations in the Southwestern United States, 2000-2003 , 2008, Journal of clinical gastroenterology.

[218]  R. Idilman,et al.  Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis , 2008, Alimentary pharmacology & therapeutics.

[219]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[220]  M. Manco,et al.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial , 2008, Hepatology.

[221]  R. Xu,et al.  Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease , 2008, Hepatology.

[222]  O. Cummings,et al.  Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. , 2008, Journal of hepatology.

[223]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[224]  M. Malinchoc,et al.  The Impact of Obesity on Long‐term Outcomes in Liver Transplant Recipients—Results of the NIDDK Liver Transplant Database , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[225]  S. Barlow,et al.  Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.

[226]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[227]  Steven P. Larson,et al.  Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[228]  G. Bedogni,et al.  Incidence and natural course of fatty liver in the general population: The Dionysos study , 2007, Hepatology.

[229]  Y. Chawla,et al.  Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. , 2007, Annals of hepatology.

[230]  J. Sauver,et al.  Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia , 2007, The American Journal of Gastroenterology.

[231]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[232]  Steven C Hunt,et al.  Long-term mortality after gastric bypass surgery. , 2007, The New England journal of medicine.

[233]  M. Holmqvist,et al.  Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.

[234]  R. Ersoy,et al.  Effects of vitamin E treatment on peroxisome proliferator‐activated receptor‐α expression and insulin resistance in patients with non‐alcoholic steatohepatitis: results of a pilot study , 2007 .

[235]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[236]  P. Puvanachandra,et al.  Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. , 2007, Clinical medicine.

[237]  R. Ersoy,et al.  Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. , 2007, Internal medicine journal.

[238]  D. Klonoff,et al.  Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. , 2007, Clinical therapeutics.

[239]  M. Manco,et al.  Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[240]  J. Dufour,et al.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[241]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[242]  Jeffrey B. Schwimmer,et al.  Prevalence of Fatty Liver in Children and Adolescents , 2006, Pediatrics.

[243]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[244]  H. Conjeevaram,et al.  Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD , 2006, The American Journal of Gastroenterology.

[245]  D. Nelson,et al.  Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[246]  Zamir Halpern,et al.  Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[247]  R. Ross,et al.  Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. , 2006, Gastroenterology.

[248]  G. Bedogni,et al.  Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[249]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[250]  P. Rosenthal,et al.  Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. , 2005, The Journal of pediatrics.

[251]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[252]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[253]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[254]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[255]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[256]  A. Jenkins,et al.  Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.

[257]  T. Reverbel da Silveira,et al.  Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. , 2005, Nutrition.

[258]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[259]  J. Clore,et al.  A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[260]  S. Malnick,et al.  Non‐alcoholic fatty liver disease – a common and benign finding in octogenarian patients , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[261]  G. Farr,et al.  Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.

[262]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[263]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[264]  S. Klein,et al.  Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[265]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[266]  A. Işık,et al.  Metformin in the treatment of patients with non‐alcoholic steatohepatitis , 2004, Alimentary pharmacology & therapeutics.

[267]  J. Hwang,et al.  Factors Associated or Related to with Pathological Severity of Nonalcoholic Fatty Liver Disease , 2004, The Korean journal of internal medicine.

[268]  K. Kaita,et al.  Fatty Infiltration of Liver in Hyperlipidemic Patients , 2000, Digestive Diseases and Sciences.

[269]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[270]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[271]  A. Işık,et al.  Metformin in the treatment of nonalcoholic steatohepatitis , 2003 .

[272]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[273]  Khusru Asadullah,et al.  Mechanisms involved in the side effects of glucocorticoids. , 2002, Pharmacology & therapeutics.

[274]  W. Dietz,et al.  Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. , 2002, Pediatrics.

[275]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[276]  P. Thuluvath,et al.  Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States , 2002, Hepatology.

[277]  A. Terano,et al.  Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001 .

[278]  Rahul Krishnarao Patil,et al.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.

[279]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[280]  A. Terano,et al.  Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. , 2001, Alimentary pharmacology & therapeutics.

[281]  T. Therneau,et al.  Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end‐stage liver disease , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[282]  K. Batts,et al.  Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. , 2000, Transplantation.

[283]  S. Caldwell,et al.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.

[284]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[285]  R. Wiesner,et al.  Weight change and obesity after liver transplantation: incidence and risk factors. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[286]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[287]  David M. Eddy,et al.  A Manual for Assessing Health Practices & Designing Practice Policies: The Explicit Approach , 1992 .

[288]  Christopher E. Smith.  United States , 1985, The Lancet.